Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)

NCT02066662 is registered in ClinicalTrials.gov with RWTH Aachen University as lead sponsor.

NCT NCT02066662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)
Lead sponsor
RWTH Aachen University
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2013
Completion date
March 31, 2020
Enrollment
192 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation or pulmonary embolism, existent coronary or valvular calcification, or both and agatston score > 50 in at least one location, need of long term oral anticoagulation therapy (oat)